Compliance & Validation — Documented
ISO 27001
SOPHiA GENETICS
Cloud platform applying AI to genomic and multimodal data analysis for precision medicine and biopharma research.
SOPHiA GENETICS, founded in 2011 and headquartered in Rolle, Switzerland, is a publicly listed company (Nasdaq: SOPH) whose DDM platform analyzes genomic and multimodal data for hospitals, laboratories, and biopharmaceutical partners. The company holds ISO/IEC 27001:2022 certification along with ISO 27017 and 27018 cloud and privacy extensions. Its biopharma offerings center on research and evidence-generation collaborations; scope and data-access models differ substantially from its clinical diagnostics business.
- Headquarters
- Rolle, Switzerland
- Founded
- 2011
- Compliance
- ISO 27001
- Deployment options
- cloud
- Website
- https://www.sophiagenetics.com
- https://www.linkedin.com/company/sophiagenetics
Categories
Vendor Scorecard
50% — Partial coverage. Coverage score — how completely Atlas documents SOPHiA GENETICS across 7 buyer-evaluation areas. Reflects available Atlas data, not solution quality.
Deployment & Hosting — Documented
cloud
Pricing Transparency — Not documented by Atlas
Ask the vendor: What is your pricing model, and what drives total cost of ownership?
Implementation & Onboarding — Not documented by Atlas
Ask the vendor: What is a realistic implementation timeline, and what onboarding support is included?
Organization & Role Fit — Documented
Academic / Research, Mid-Size Biotech, Large Pharma, Data Engineer / Architect, Data Management, R&D Leadership
Solution Scope — Not documented by Atlas
Data & AI Infrastructure
Company Viability — Partially documented
Public, Founded 2011
Always ask the vendor
Not captured in Atlas data — confirm directly. Excluded from the score above.
Data Rights & IP
Who owns model outputs? Is our proprietary data used to train models others can access, and where does our data reside?
Model Credibility & Explainability
Can you share validation studies or benchmarks, explain how the model reaches its conclusions, and describe how bias and drift are monitored?
Clinical Trial Activity
1 registered trial where SOPHiA GENETICS is the lead sponsor. Source: ClinicalTrials.gov, verified 2026-07-29.
Top conditions studied: Non-small Cell Lung Cancer Metastatic
- Predictive Multimodal Signatures Associated With Response to Treatment and Prognosis of Patients With Stage IV Non-small Cell Lung Cancer (NCT04994795, active not recruiting)
Questions to Ask This Vendor
- What does a biopharma data collaboration look like contractually and technically?
- Which data types beyond genomics are supported in multimodal analysis?
- How is patient consent and data governance handled across the hospital network?
- What evidence supports the platform's analytical performance in our application?